Regenacy Pharmaceuticals is a pioneer in developing novel treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme ("HDAC") inhibitors.
We were founded in December 2016 following the acquisition of Acetylon Pharmaceuticals by Celgene. Regenacy received exclusive rights to the clinical stage, orally bioavailable, HDAC6 selective inhibitor, ricolinostat (ACY-1215), for a range of non-cancer disease indications including peripheral neuropathy, polycystic kidney disease and cholangiocarcinoma. Regenacy also has a unique and proprietary portfolio of selective HDAC1,2 inhibitors with significant potential for treating hemoglobinopathies, cognitive dysfunction and leukemia.
Histone deacetylases (HDACs) are a family of 18 related enzymes found in all human cells that remove acetyl groups from intracellular proteins. This activity is critical in maintaining normal gene expression and protein function throughout the cell, tissues and body. Disruption of protein acetylation contributes to a wide range of major medical conditions. Currently marketed HDAC inhibitors lead to significant side-effects by indiscriminate targeting of multiple HDACs. Regenacy’s selective HDAC inhibitors have a greatly improved safety profile, reduce abnormal function of specific HDAC enzymes and can regenerate normal biological function.
Regenacy’s focus is the development of oral, selective HDAC inhibitor compounds to address major areas of unmet clinical need including diabetic and chemotherapy-induced peripheral neuropathy, polycystic kidney disease and cholangiocarcinoma, sickle cell disease and beta thalassemia, cognitive dysfunction and leukemia.